New antibiotic compound enters phase 1 clinical trial
Novacta Biosystems has commenced dosing of the first healthy volunteers in a phase 1 clinical…read more
Novacta is a drug discovery and development company using pathway engineering and chemistry to optimise the activity of natural products for the treatment of infectious diseases. The company combines proprietary technologies from the world-renowned Actinomycete group of the John Innes Centre, Norwich with the know-how of a highly experienced team drawn from major pharmaceutical companies and the biotechnology industry.
Associated Fund Rainbow Seed Fund
Sector Medical / Biotechnology